Blood Test for Calprotectin Could Predict Which COVID-19 Patients Are at Risk of Decline
By HospiMedica International staff writers Posted on 15 Dec 2020 |
Illustration
Two different research teams have shown that a blood test for calprotectin could predict which COVID-19 patients are at risk of decline, enabling hospitals to better allocate essential resources.
The findings of the test that could predict COVID-19 severity were presented at the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo. Using this test, the first team from Karolinska Institute (Solna, Sweden) and Gentian Diagnostics (Stockholm, Sweden) found that ICU patients with COVID-19 had significantly higher calprotectin levels compared with ICU patients without COVID-19. The second team, led Hospital Universitario Santa Lucía (Cartagena, Spain), then found that calprotectin levels were significantly higher in COVID-19 patients who required mechanical ventilation and/or died compared with other non-severe COVID-19 patients.
The second team also compared the calprotectin test's performance with that of other tests for COVID-19 severity that are currently in use. Out of the other tests they studied, they found that a test for C-reactive protein (CRP) was the only one that predicted both patient need for mechanical ventilation and mortality as accurately as calprotectin.
"The important difference between CRP and calprotectin is that calprotectin is a much faster biomarker for inflammation and infection, and an earlier indicator that a patient is getting worse," said Aleksandra Mandic Havelka, PhD, from Karolinska Institute, who also worked on the second study. "This means that calprotectin is better suited for making urgent decisions about which COVID-19 patients need to be prioritized and treated with the optimal level of care."
Related Links:
Karolinska Institute
Gentian Diagnostics
The findings of the test that could predict COVID-19 severity were presented at the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo. Using this test, the first team from Karolinska Institute (Solna, Sweden) and Gentian Diagnostics (Stockholm, Sweden) found that ICU patients with COVID-19 had significantly higher calprotectin levels compared with ICU patients without COVID-19. The second team, led Hospital Universitario Santa Lucía (Cartagena, Spain), then found that calprotectin levels were significantly higher in COVID-19 patients who required mechanical ventilation and/or died compared with other non-severe COVID-19 patients.
The second team also compared the calprotectin test's performance with that of other tests for COVID-19 severity that are currently in use. Out of the other tests they studied, they found that a test for C-reactive protein (CRP) was the only one that predicted both patient need for mechanical ventilation and mortality as accurately as calprotectin.
"The important difference between CRP and calprotectin is that calprotectin is a much faster biomarker for inflammation and infection, and an earlier indicator that a patient is getting worse," said Aleksandra Mandic Havelka, PhD, from Karolinska Institute, who also worked on the second study. "This means that calprotectin is better suited for making urgent decisions about which COVID-19 patients need to be prioritized and treated with the optimal level of care."
Related Links:
Karolinska Institute
Gentian Diagnostics
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans